Visiongain Publishes Bacterial Conjunctivitis Market Report to 2031

22 February 2021
Pharma

Visiongain has published a new report on Bacterial Conjunctivitis Market Report to 2031. Profiles of Leading Bacterial Conjunctivitis Market players, Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Bacterial Conjunctivitis Market Report Market was valued at US$XXX billion in 2021 and is projected to reach at a market value of US$XXX billion by 2031. A conjunctivitis is a communicable disease which is also known as pink eye in the US. The bacterial conjunctivitis is an inflammation of the conjunctiva which can be caused by bacteria, viruses, and allergens. It is a highly contagious disease that can be easily transmitted from one person to the other through touching objects of infected person, coughing and sneezing. Bacterial conjunctivitis can be caused by both the gram-positive bacteria and gram-negative bacteria. Staphylococcus aureus, Pseudomonas, Serratia marcescens, Haemophilus influenza, are the most common bacteria that are responsible for this disease. Its symptoms include the reddening of the eyes, rolling tears, thick yellow discharge, itching, burning sensation, blurred vision, and heightened sensitivity towards the light.

There are various factors that are driving the global bacterial conjunctivitis market which includes the growing incidence and prevalence of conjunctivitis, growing clinical trials, and increasing pipeline of products that are used for the treatment of conjunctivitis. In addition, the rising healthcare expenditure, growing disposable income, robust R&D exploration will benefit the global bacterial conjunctivitis market in future. However, the expiry of patents and side effects associated with the treatment will affect the growth of the market.

COVID-19 Impact on the Global Bacterial Conjunctivitis Market
The COVID-19 pandemic impacted the global Bacterial Conjunctivitis market. It affected the growth of the market since in the first quarter of 2020, there were series of lockdowns in major developed and emerging economies. Most of the countries in EU, Korea, Japan, India, China, among others, enforced strict lockdown to contain the spread of the virus. It was originated from the Wuhan city of the mainland China, in December 2019. However, it reached to over 200 countries in next few months. According to worldometers, over 57.89 million cases of COVID-19 were registered till 21st November 2020 with over 1.37 million fatalities worldwide.

Market Drivers
Rising incidence and prevalence of conjunctivitis
There is significant rise in the incidence and prevalence rate of conjunctivitis across the world. Conjunctivitis affects millions of people around the globe and put economic and social burden on the emerging economies such as China, India, and Korea. It is widely prevailed in the US, China, India, and other EU region. According to NCBI, it is estimated that the acute conjunctivitis affects over 6 million people in the US every year. The cost of bacterial conjunctivitis treatment is estimated to exceed $377 million to $857 million per year. Many US state health departments, students in the US have to mandatory be treated with topical antibiotic eyedrops irrespective of the underline cause of conjunctivitis, before returning to school.

Improved eye care system in hospitals and clinics worldwide
All the hospitals and clinics are well equipped to treat conjunctivitis. It is not mandatory to visit the specialized eye hospitals to get treated for the conjunctivitis disease. Most of the conjunctivitis patients are operated by the primary care doctors rather than specialized eye care professionals. In the US alone, around 1.0% of all primary care office visits are related to conjunctivitis. About 70.0% of all the patients with acute conjunctivitis are handled in the primary care and urgent care. There are various eye care hospitals, clinics, research institutes, among others that provide specialized care for the patients. For instance, Moorfields Eye Hospital, Cleveland Clinic, Wills Eye Hospital, Aravind Eye Care System, ophthalmology clinics, among others, provide well equipped eye care for the conjunctivitis patients.

Market Opportunities

Disposable income is increasing in emerging economies
Emerging economies such as Korea, Thailand, India, and China are on a roll in gaining traction owing to the growing disposable income and cohesive government regulations. For instance, the disposable income of China increased to $6,460 in 2019 from $5,986 in 2018. The rising disposable income opened new opportunities for Bacterial Conjunctivitis market players. The demand for the Bacterial Conjunctivitis is increasing significantly and it is expected to continue the growing trend.

Increasing healthcare expenditure
Government policies from around the globe are paying huge attention on improving the healthcare system through increasing healthcare budget and drafting cohesive policies. Healthcare system is getting support from the governments worldwide. Rising healthcare spending has boosted the healthcare system of the world. For instance, the US spends around $10,000 per individual, which is the highest healthcare spending across the world. Other developed economies such as the UK, Germany, Canada, among others, invests significant amount of money in the healthcare system. Even the emerging economies including China, Korea, India, and Korea are also increasing their healthcare expenditure.

Huge contribution from the market players
Bacterial Conjunctivitis market players such as Bayer AG, Hoffman-LaRoche, Ltd., Merck & Co., Novartis AG, Pfizer, Inc., Akorn, Inc., Allergan, Inc., Perrigo Company plc, Santen Pharmaceutical Co., Ltd., Valeant Pharmaceuticals International, Inc. among others, are contributing significantly into the growth of the global conjunctivitis market. These players are adopting various strategies to cater the opportunities in the market. For instance, R&D, product launch, collaboration, partnership, among others are widely tested by the market players to grow significantly.

Rising cases of conjunctivitis in babies
Huge pool of new-borns is getting infected from the bacterial conjunctivitis. New-borns and infants who suffer from this condition are vulnerable against serious complications. Thus, treatment of this condition can’t be delayed. All the major hospitals, clinics and institute provide active support to treat new-borns without any delay. Ointment or prescribed eye drops are suggested for the babies after getting conjunctivitis. Other types of conjunctivitis in new-borns include chemical, bacterial, inclusion, and even childhood conjunctivitis and may go away within a couple of weeks in the supervision of the physicians.

Competitive Landscape
Visiongain report covers detailed competitive landscape which includes overview of key players operating, extensive product portfolios, recent developments, among others. Some of the company’s profiled in this report include Bayer AG, Hoffman-La Roche, Ltd., Merck & Co., Novartis AG, Pfizer, Inc., Akorn, Inc., Allergan, Inc., Perrigo Company plc, Santen Pharmaceutical Co., Ltd., Valeant Pharmaceuticals International, Inc., among others. The global bacterial conjunctivitis market players adopt various strategies to cater the available opportunities in the market. The rising investment in R&D, regular product launches, partnerships, collaborations, new product developments, and so on, are the key strategies adopted by the market players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Big Data Analytics in Healthcare Market Report 2021-2031

Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.

13 May 2021

Read

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever